NCT03445468View on ClinicalTrials.gov

Immunogenicity and Safety for 'IL-YANG Quadrivalent Influenza Vaccine' in Healthy Korean Children and Adolescents

PHASE3CompletedINTERVENTIONAL
Enrollment

379

Participants

Timeline

Start Date

September 20, 2017

Primary Completion Date

December 29, 2017

Study Completion Date

August 30, 2018

Conditions
Influenza, Human
Interventions
BIOLOGICAL

IL-YANG Quadrivalent Influenza Vaccine

A single 0.5mL dose administrated as an intramuscular injection.

BIOLOGICAL

IL-YANG Flu Vaccine Pre-filled Syringe

A single 0.5mL dose administrated as an intramuscular injection.

Trial Locations (1)

06591

The catholic university of Korea, Seoul ST. Marry's Hospital, Seoul

All Listed Sponsors
lead

Il-Yang Pharm. Co., Ltd.

INDUSTRY

NCT03445468 - Immunogenicity and Safety for 'IL-YANG Quadrivalent Influenza Vaccine' in Healthy Korean Children and Adolescents | Biotech Hunter | Biotech Hunter